US scrutiny of Chinese biotech companies has intensified in recent years, and the proposed BIOSECURE Act adds pressure on global investors to review their exposure to potentially problematic firms. This note evaluates the risk profiles of the 30 most prominent Chinese biotech firms to determine which are most likely to come into the crosshairs of regulators and politicians.
For access to the full note, contact us at mper@rhg.com.